GlobeNewswire Inc | Nov 12, 2020 07:00AM EST

November 12, 2020

NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Presentation Details:

Event Jefferies Virtual London Healthcare ConferenceFormat: Fireside chatDate Thursday, November 19, 2020Time 5:00 p.m. GMT/12:00 p.m. ESTEvent SVB Leerink Oncology 1x1 DayFormat: One-on-one meetingsDate Thursday, November 19, 2020

A live webcast of the Jefferies fireside chat will be accessible through the Investors section of the Companys website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.

About Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visitwww.zentalis.com. Follow Zentalis on Twitter at@ZentalisPand on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:

Thomas Hoffmann

Solebury Trout

1.646.378.2931

thoffmann@soleburytrout.com

Media Contact:

Julia Deutsch

Solebury Trout

1.646.378.2967

jdeutsch@soleburytrout.com